deltatrials
Unknown PHASE1 INTERVENTIONAL 2-arm NCT05262179

A Phase 1 Clinical Trial to Explore Systemic Exposure of CTO0101 Eye Drops, Safety and Local Tolerability in Healthy Adults

Sponsor: Taejoon Pharmaceutical Co., Ltd.

Conditions Healthy
Interventions CTO0101 Placebo (vehicle)
Updated 5 times since 2022 Last updated: Feb 21, 2022 Started: Oct 5, 2021 Primary completion: May 27, 2022 Completion: Jul 5, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05262179, this PHASE1 trial focuses on Healthy and remains ongoing. Sponsored by Taejoon Pharmaceutical Co., Ltd., it has been updated 5 times since 2021, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Apr 2022 – ~Mar 2024 · 23 months · monthly snapshotRecruiting~Mar 2024 – ~Jul 2024 · 4 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotUnknown~Sep 2025 – present · 12 months · monthly snapshotUnknown

Change History

5 versions recorded

  1. Sep 2025 — Present [monthly]

    Unknown PHASE1

  2. Sep 2024 — Sep 2025 [monthly]

    Unknown PHASE1

  3. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE1

    Status: Unknown Status → Unknown

  4. Mar 2024 — Jul 2024 [monthly]

    Unknown Status PHASE1

    Status: Recruiting → Unknown Status

  5. Apr 2022 — Mar 2024 [monthly]

    Recruiting PHASE1

    First recorded

Oct 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Taejoon Pharmaceutical Co., Ltd.
Data source: Taejoon Pharmaceutical Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations